Provides cloud-based cancer diagnostic services using whole-genome sequencing and AI-driven algorithms to detect minimal residual disease (MRD) in blood samples. This approach enables faster results, requires less blood, and offers a comprehensive view of tumor genetic landscapes, improving early detection and monitoring for pharmaceutical and diagnostic organizations.
Funding
Funding not disclosed
Founders
Product
Problem
Monitoring cancer recurrence requires invasive tissue biopsies or frequent imaging, which can be costly, time-consuming, and expose patients to radiation. Existing liquid biopsy methods may lack the sensitivity to detect minimal residual disease (MRD) at early stages, hindering timely intervention and personalized treatment strategies.
Solution
Veracyte MRD offers a cloud-based cancer diagnostic service that uses whole-genome sequencing and AI-driven algorithms to detect minimal residual disease (MRD) from a single tube of blood. The assay characterizes the complete set of cancer mutations in the tumor tissue sample and blood, then applies artificial intelligence to detect traces of cancer in subsequent blood samples during follow up. This approach offers a comprehensive view of the tumor's genetic landscape, enabling earlier detection of recurrence and improved monitoring of treatment response. The platform's AI-driven pipeline generates patient-specific signatures, allowing accurate and robust tracking of tumor progression as it evolves during treatment and follow-up.
Target Audience
The primary customers are pharmaceutical and diagnostic organizations, as well as clinical researchers, seeking to improve early cancer detection, monitor treatment response, and develop personalized therapies.
Features
- Whole-genome sequencing to identify cancer variants across the entire genome
- AI-driven algorithms for pattern recognition and sensitive detection of residual disease
- In silico patient-specific signature development for accurate tumor tracking
- Requires less than 4ml of plasma from a single blood draw
- Faster results compared to traditional methods
- Cloud-based platform for data analysis and reporting